MedTech
Biopharma firm SynOx secures $35m in debt funding
News comes just days after the late-stage biopharma company raises $75 in funding
SynOx Therapeutics, a Dublin-headquartered late-stage clinical biopharmaceutical company, has secured $35 million in debt funding just days after raising $75 million from investors.
The company was founded in 2020 after securing worldwide rights to develop a drug candidate called Emactuzumab under a licence agreement with Roche.